Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· Matt KaeberleinAudio: American English

Ora Biomedical video: 10,000 longevity experiments, peptides and resilience

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →

At a glance

Automatic summary · not editorially reviewed

In this video description, Ora Biomedical's CEO and CSO describe screening interventions for lifespan and healthspan, including about 300 peptides, and an emerging focus on resilience; the description reports a longevity-associated compound that reduced radiation dermatitis burden by about 40% in a mouse model. [1]

  1. The description says the episode covers Ora's systematic screening of interventions for lifespan and healthspan, including a screen of roughly 300 peptides and lessons from nearly 10,000 intervention experiments. [1]

  2. The description says resilience led Ora from lifespan studies in C. elegans to UV and radiation resistance, human skin cells, animal studies and possible applications such as photoaging, cancer radiation therapy and radiation protection for pilots and astronauts. [1]

  3. The description reports early pipeline results including a longevity-associated compound that reduced radiation dermatitis burden by approximately 40% in a mouse model. [1]

Ora's screening of peptides and 10,000 experiments

According to the description, the episode is an update on Ora Biomedical's effort to systematically screen interventions for effects on lifespan and healthspan. The hosts describe the Million Molecule Challenge and new results from a screen of roughly 300 peptides, including known peptides, AI-predicted candidates and structurally diverse molecules. They also discuss what Ora is beginning to learn from nearly 10,000 intervention experiments and why existing datasets may not be sufficient to predict longevity therapeutics with AI. [1]

Resilience: from worms to UV, radiation and skin

The description says an unexpected direction is resilience: rather than asking only whether a molecule extends lifespan, can longevity interventions improve the body's ability to recover from damage? That question reportedly led Ora from lifespan studies in C. elegans to UV and radiation resistance, human skin cells, animal studies and potential applications such as photoaging, cancer radiation therapy and protecting pilots and astronauts from radiation exposure. Early pipeline results mentioned include a longevity-associated compound that reduced radiation dermatitis burden by approximately 40% in a mouse model, and work on natural products that may improve recovery from UV damage. [1]

Translation from worms to humans and disclosure

The description states that the conversation also covers the challenge of translating discoveries from worms into humans and whether resilience could offer a practical path for testing longevity therapeutics on a much shorter timescale. The host discloses that he is a co-founder of Ora Biomedical, serves on its Board of Directors and has a financial interest in the company, so viewers can weigh this potential conflict of interest. The description also carries a general educational disclaimer and states that the information is not personalized medical advice. [1]

Context & limits

This is based only on the supplied video description; the video and transcript were not reviewed. The description reports no study designs, sample sizes, follow-up or statistical uncertainty for the cited results, and the approximately 40% reduction comes from a mouse model, not humans. The host discloses a financial interest in Ora Biomedical.

Based on the creator’s description; the full video and transcript were not analyzed.

[1] Peptides, Astronauts, and AI: Lessons from the First 10,000 Longevity Experiments at Ora Biomedical
Quoted passages in the original language
systematically screen interventions for effects on lifespan
from lifespan studies in C. elegans to
reduced radiation dermatitis burden by approximately 40%

About this video

Creator description · original textText language: American English

Subscribe to our channel: https://www.youtube.com/@mkaeberlein What can we learn from the first 10,000 experiments in the search for interventions that extend healthy lifespan? In this episode of Longevity Science, I sit down with Dr. Ben Blue, CEO of Ora Biomedical, and Dr. Blair Zhao, CSO, for an update on Ora’s effort to systematically screen interventions for effects on lifespan and healthspan. We start with the Million Molecule Challenge and some intriguing new results from a screen of roughly 300 peptides, including known peptides, AI-predicted candidates, and structurally diverse molecules. We discuss what Ora is beginning to learn from nearly 10,000 intervention experiments, why existing datasets may not be sufficient to predict longevity therapeutics with AI, and how large-scale experimental data could eventually change that. We also explore an unexpected direction emerging from these experiments: resilience. Rather than asking only whether a molecule extends lifespan, can longevity interventions improve the body's ability to recover from damage? That question has led Ora from lifespan studies in C. elegans to UV and radiation resistance, human skin cells, animal studies, and potential applications ranging from photoaging and cancer radiation therapy to protecting pilots and astronauts from radiation exposure. Along the way, Ben and Blair share early results from Ora’s pipeline, including a longevity-associated compound that reduced radiation dermatitis burden by approximately 40% in a mouse model, as well as work on natural products that may improve recovery from UV damage. We also discuss the challenge of translating discoveries from worms into humans and whether resilience could provide a practical path for testing longevity therapeutics on a much shorter timescale. Disclosure: I am a co-founder of Ora Biomedical and serve on its Board of Directors. I have a financial interest in the company. This relationship is disclosed so viewers can appropriately consider this potential conflict of interest when evaluating the discussion. Topics include: the Million Molecule Challenge, AI and longevity drug discovery, peptide therapeutics, C. elegans, mTOR, stress resilience, UV damage, radiation therapy, skin aging, natural products, astronauts and spaceflight, and translating longevity interventions to humans. DISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find me: Instagram: https://www.instagram.com/mkaeberlein/ LinkedIn: https://www.linkedin.com/in/mkaeberlein/ Twitter: https://twitter.com/mkaeberlein Facebook: https://www.facebook.com/matt.kaeberlein/ --- Hi, I'm Matt Kaeberlein. I spent the first few decades of my career doing scientific research into the biology of aging, trying to understand the finer details of how humans age in order to facilitate translational interventions that promote healthspan and improve quality of life. Now I want to take some of that knowledge out of the lab and into the hands of people who can really use it. On this channel I talk about all things aging and healthspan, from supplements and nutrition to the latest discoveries in longevity research. My goal is to lift the veil on the geroscience and longevity world and help you apply what we know to your own personal health trajectory. I care about quality science and will always be honest about what I don't know. I hope you'll find these episodes helpful!

Matt Kaeberlein · 43 min · Source published: 2026-10-06

Added to Harbor: 10/23/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…